Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,192 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Not applicable Interventional Results available

Y90 Radiation Segmentectomy vs SBRT for HCC

NCT04235660
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
0 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • New Haven, Connecticut • Orlando, Florida + 6 more
Conditions
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions
ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
Conditions
Healthy, Liver Diseases, Obesity
Interventions
BI 456906
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Conditions
Hepatocellular Carcinoma
Interventions
BBI608, BBI503, Sorafenib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • Coronado, California + 25 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

CM for Patients With ALD After Liver Transplant

NCT06304467
Conditions
Alcohol Use Disorder, Alcohol; Liver, Post Liver Transplant, Contingency Management, Alcohol Liver Disease
Interventions
Contingency Management
Behavioral
Lead sponsor
Arpan A. Patel, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Recruiting Not applicable Interventional Accepts healthy volunteers

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

NCT06335771
Conditions
Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
Interventions
Dietary consultation weight loss intervention
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Hepatitis C
Interventions
LADR Treatment
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 5 more
Conditions
Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
Interventions
skin punch biopsy
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Conditions
Hepatocellular Carcinoma
Interventions
Exercise intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Colorectal Cancer, Colorectal Neoplasms, Colorectal Cancer Screening
Interventions
MyChart Priming Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
51 Years to 75 Years
Enrollment
3,880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Conditions
Hematological Diseases
Interventions
Liver Biopsy and MRI T2* MRI
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions
No interventions
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
8
States / cities
Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more
Conditions
Liver Cirrhosis
Interventions
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more
Conditions
Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
Interventions
HBIG, Epivir, Hepsera
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Interventions
Observational Protocol
Other
Lead sponsor
European Foundation for Study of Chronic Liver Failure
Other
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Timeline
2021 – 2026
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
lapatinib ditosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Sacramento, California
Conditions
End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions
HEPLISAV-B®
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
Recruiting No phase listed Observational Accepts healthy volunteers

DILIN - Prospective Study

NCT00345930
Conditions
Liver Diseases
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
2 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 3 more
Conditions
Veno-occlusive Disease
Interventions
Defibrotide, Best Supportive Care
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Conditions
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California